Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sanjal Desai, Michael Alexander Spinner, Kevin A. David, Veronika Bachanova, Gaurav Goyal, Raya Saba, Kathleen Anne Dorritie, Jacques Mario Azzi, Elyse Harris, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Uroosa Ibrahim, Siddharth Iyengar, Katherine Cynthia Rappazzo, Firas Baidoun, Victor Manuel Orellana-Noia, Catherine S. Magid Diefenbach, Ranjana H. Advani, Ivana N. M. Micallef
Institutions: University of Minnesota, Stanford Cancer Institute, Rutgers Cancer Institute, Mayo Clinic, Saint Joseph Hospital, UPMC Hillman Cancer Center, New York University, University of Wisconsin–Madison, UW Health University Hospital, University of Minnesota Medical Center, University of Alabama at Birmingham, Icahn School of Medicine at Mount Sinai, University of Miami, Vanderbilt University Medical Center, Cleveland Clinic, Rhode Island Hospital, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Stanford University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286293559